Survival analysis showed that survival time was significantly lower in the RARRES3 high-expression group than in the low-expression group in the TCGA-PAAD cohort (P=0.016) (Figure 9A). The gene discussed is PLAAT4; the disease is pancreatic adenocarcinoma.